Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)
4.820
+0.100 (2.12%)
Feb 4, 2026, 3:04 PM CST
SHE:002793 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -677.2 | -965.5 | -661.14 | -1,225 | 406.1 | 320.7 |
Depreciation & Amortization | 204.3 | 204.3 | 208.29 | 231.31 | 199.78 | 170.69 |
Other Amortization | 7.29 | 7.29 | 14.25 | 42.06 | 12.46 | 13.49 |
Loss (Gain) From Sale of Assets | -0.24 | -0.24 | 12.18 | -1.74 | 3.31 | 5.42 |
Asset Writedown & Restructuring Costs | 229.97 | 229.97 | 56.64 | 93.09 | 103.44 | 90.81 |
Loss (Gain) From Sale of Investments | 3.45 | 3.45 | -15.05 | -168.31 | 2.18 | -6.28 |
Provision & Write-off of Bad Debts | 14.12 | 14.12 | 54.97 | - | - | - |
Other Operating Activities | 418.28 | 264 | 37.73 | 99.18 | 120.1 | 70.02 |
Change in Accounts Receivable | -17.52 | -17.52 | 791.71 | 689.64 | -733.09 | -483.78 |
Change in Inventory | -79.29 | -79.29 | 168.47 | -52.04 | -70.37 | 70.27 |
Change in Accounts Payable | 81.46 | 81.46 | -365.76 | -383.63 | 139.91 | -300.33 |
Change in Other Net Operating Assets | 2.57 | 2.57 | 27.27 | - | -5.56 | 5.93 |
Operating Cash Flow | 284.73 | -157.85 | 466.89 | -939.13 | 120.63 | -32.75 |
Capital Expenditures | -44.08 | -115.35 | -242.39 | -194.82 | -309.03 | -360.89 |
Sale of Property, Plant & Equipment | 3.27 | 5.32 | 6.85 | 3.07 | 2.13 | 5.46 |
Cash Acquisitions | - | - | - | -1.93 | -4.58 | -3.2 |
Divestitures | 43.98 | 101.65 | - | -8.73 | - | 25.94 |
Investment in Securities | -5.9 | 5.1 | 98.7 | 65.35 | -81.55 | 491.13 |
Other Investing Activities | 26.05 | 1.95 | 1,094 | 17.87 | -35.39 | -57.93 |
Investing Cash Flow | 23.31 | -1.34 | 957.43 | -119.18 | -428.42 | 108.26 |
Long-Term Debt Issued | - | 1,034 | 1,028 | 2,254 | 1,459 | 1,000 |
Long-Term Debt Repaid | - | -890.71 | -3,277 | -2,312 | -873.92 | -831.61 |
Net Debt Issued (Repaid) | -257.94 | 142.96 | -2,249 | -58.44 | 585.14 | 168.73 |
Issuance of Common Stock | 36.99 | 36.99 | - | - | - | 70.8 |
Repurchase of Common Stock | -100 | -100 | - | -40.66 | -30.14 | - |
Common Dividends Paid | -52.69 | -61.19 | -76.78 | -138.26 | -132.33 | -136.09 |
Other Financing Activities | 44.31 | -152.88 | 644.73 | 622.35 | 366.86 | 27.27 |
Financing Cash Flow | -329.34 | -134.13 | -1,681 | 384.98 | 789.53 | 130.71 |
Foreign Exchange Rate Adjustments | -0.68 | 2.76 | 2.18 | 14.1 | -1.13 | -19.3 |
Net Cash Flow | -21.97 | -290.55 | -254.41 | -659.23 | 480.61 | 186.92 |
Free Cash Flow | 240.65 | -273.2 | 224.5 | -1,134 | -188.4 | -393.64 |
Free Cash Flow Margin | 9.66% | -10.32% | 9.50% | -31.61% | -2.91% | -6.46% |
Free Cash Flow Per Share | 0.23 | -0.26 | 0.21 | -0.80 | -0.13 | -0.27 |
Cash Income Tax Paid | 149.94 | 102.04 | -7.95 | 581.21 | 645.92 | 470.19 |
Levered Free Cash Flow | 470.3 | 47.69 | 1,338 | -623.17 | -626.37 | -579.75 |
Unlevered Free Cash Flow | 508.15 | 87.93 | 1,386 | -546.5 | -560.63 | -548.27 |
Change in Working Capital | 84.75 | 84.75 | 759.01 | -9.79 | -726.73 | -697.61 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.